Curriculum Vitae – Dr. Zoltan Ivics

  • Ausbildung und Laufbahn

    1983–1988 University of Agricultural Sciences, Gödöllô, Hungary
    1988 Diploma (M.Sc.), Agricultural Sciences, English-Hungarian technical translation
    1988–1994 Graduate Studies in Molecular Biology, University of Agricultural Sciences/Gödöllô/Hungary and University of Minnesota, St. Paul, USA
    1988-1991 Research Assistant, Agricultural Biotechnology Research Center, Gödöllô, Hungary
    1991-1994 Visiting Research Fellow, University of Minnesota, USA
    1994 Ph.D., University of Agricultural Sciences, Gödöllô, Hungary
    1994-1997 Postdoctoral Associate, University of Minnesota, USA
    1997-1997 Research Associate, University of Minnesota, USA
    1997-1999 Visiting Scientist, The Netherlands Cancer Institute, The Netherlands
    1999-2011 Group Leader, Max Delbrück Center for Molecular Medicine, Berlin, Germany
    Seit 2010 Professor, University of Debrecen, Debrecen, Hungary
    Seit 2011 Head of Division, Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany
    2013 Doctor of the Hungarian Academy of Sciences (D.Sc.)
  • Preise und Auszeichnungen

    1988 Hungarian Academy of Sciences, doctorate fellowship
    1996 Human Frontier Science Program Organization (HFSPO), short-term postdoctoral research fellowship
    1997 Organization for Economic Cooperation and Development (OECD), postdoctoral research fellowship
    2009 Molecule of the Year 2009 – International Society for Molecular and Cell Biology and Biotechnology Protocols and Researches
  • Wissenschaftliche Erfolge

    Molecular reconstruction of the Sleeping Beauty transposable element. Sleeping Beauty not only represents the first DNA-based transposon ever shown to be active in cells of vertebrates, but the first functional gene ever reconstructed from inactive, ancient genetic material, for which an active, naturally occurring copy either does not exist or has not yet been isolated. Technologies based on Sleeping Beauty gene transfer have
    been revolutionizing genomic manipulations in vertebrate species. Prof. Ivics has published >80 manuscripts in peer reviewed journals, with a total Impact Factor of >600 and >4500 citations (h-index: 36), and is co- inventor on 9 patents. He got invited to ~25 national and international symposia as an invited speaker or keynote speaker in the last ten years. Since 2000 his research efforts were supported by 16 research grants from the German Research Foundation, the German Ministry of Education and Research, the European Commission, and the Volkswagen Stiftung.

  • Führungserfahrung

    Prof. Ivics is Head of Division at the Division of Medical Biotechnology (http://www.pei.de/EN/research/groups/medical-biotechnology/medical-biotechnology-research-node.html) at the Paul Ehrlich Institute. He was coordinator and co-coordinator of the Specific Targeted Research Projects JUMPY (FP5), and INTHER of the European Commission (FP6), and he is currently coordinating the ReGene program project funded by the German Ministry of Education and Research. He has been serving as Member of the Board of the European Society of Gene and Cell Therapy (ESGCT) since 2012. Prof. Ivics was co-organizer of the 6th Annual International Conference on Transposition and Animal Biotechnology (Berlin, Germany, 2008), a workshop on Recombinase-mediated Gene Transfer (Brugge, Belgium, 2008), the FASEB Summer Research Conference „Mammalian Mobile DNA” (Big Sky, Montana, USA, 2013) and organizer/conference chair of the Conference on Transposition and Genome Engineering (Budapest, Hungary, 2013). He is faculty member of the Center for Cell and Gene Therapy of the LOEWE (Landes- Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz) program in Hessen, Germany.

  • Andere Aktivitäten

    Prof. Ivics served as co-editor of a special issue of Genome Biology entitled “Transposons in Vertebrate Functional Genomics” containing 16 review articles, and a special issue of Seminars in Cancer Biology entitled “Repetitive Elements and Genome Instability” containing 8 review articles written by leaders of the field. He edited a special Hot Topic issue of Current Gene Therapy entitled “Recombinase Technologies for Gene Therapy” containing 8 review articles written by leaders of the field. He is member of the Editorial Boards of Molecular Therapy, Mobile DNA, Mobile Genetic Elements, Journal of RNAi and Gene Silencing, The Open Gene Therapy Journal and Molecular Therapy – Nucleic Acids. Eight PhD students obtained a doctoral degree under his guidance, and all of them obtained postdoctoral positions in academia and industry.